465. Does a Detectable Viral Load During Hepatitis C Treatment at Week 4 Predict Virologic Failure in an 8-Week Course of Ledipasvir-Sofosbuvir in Treatment-Naïve Patients with Genotype 1 Infection without Cirrhosis?
Session: Poster Abstract Session: Hepatitis C
Thursday, October 27, 2016
Room: Poster Hall
Posters
  • detectable4weekVLharvoni8weekIDWeek2016poster.pdf (666.6 kB)
  • Background: Treatment of hepatitis C virus (HCV) with a shorter duration of 8 weeks of ledipasvir-sofosbuvir has resulted in high rates of sustained virologic response (SVR) similar to a 12-week duration in treatment-naïve patients with genotype 1 infection without cirrhosis. This treatment strategy yields the opportunity to significantly reduce healthcare costs and associated adverse effects. The objective of this study is to assess if a detectable viral load at Week 4 predicts failure for an 8-week course of ledipasvir-sofosbuvir.

    Methods: A retrospective, quality assurance chart review was conducted at the W.G. (Bill) Hefner VA Medical Center in Salisbury, North Carolina, where 333 patients have completed a HCV treatment course of ledipasvir-sofosbuvir from January 2015 to May 2016. Treatment-naïve, HCV genotype 1 patients without cirrhosis who received 8 weeks of ledipasvir-sofosbuvir were assessed. The association between SVR and detectable HCV viral loads at Week 4 of treatment using COBAS AMPLIPREP/TaqMan with a lower limit of quantification of 15 international units (IU) per milliliter was evaluated.

    Results: Overall, 38 of 44 patients (86.4%) of patients receiving 8 weeks of ledipasvir-sofosbuvir achieved SVR. Of the 38 patients that achieved SVR, 30 (78.9%) patients had nondetectable viral loads at Week 4 of treatment whereas 8 patients (21.1%) had a detectable viral load at week 4 (p = 0.96). For the 5 patients that relapsed on 8 weeks of ledipasvir-sofosbuvir, 4 patients (80%) had nondetectable viral loads at Week 4 of treatment whereas 1 patient (20%) had a detectable viral load at Week 4.

    Conclusion: Detectable viral loads at week 4 do not appear to negatively impact SVR in treatment-naïve, HCV genotype 1 patients without cirrhosis treated with 8 weeks of ledipasvir-sofosbuvir. Additionally, relapse is possible despite nondetectable viral loads during treatment.

    Bailey Guest, PharmD, Pharmacy, W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Charles De Comarmond, MD, Wake Forest University, Winston-Salem, NC, Hendren Bajillan, MD, Infectious Diseases, W.G. (Bill) Hefner VA Medical Center, Salisbury, NC and John Sanders, MD MPH&TM, Wake Forest Baptist Health, Winston-Salem, NC

    Disclosures:

    B. Guest, None

    C. De Comarmond, None

    H. Bajillan, None

    J. Sanders, None

    See more of: Hepatitis C
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.